INVO Bioscience Inc (OTCQB: IVOB), a medical device company focused on treating infertility with its FDA-cleared INVOcell product, announced on Thursday that it has named Inger Britt Carlsson, PhD as its new vice president of Medical Affairs.

Dr Carlsson will be developing and managing the company's educational symposiums, generating scientific abstracts/publications on the INVOcell technology, and building relationships with key opinion leaders around the world.

Dr Carlsson has more than 30 years' experience in the fertility industry. She was most recently global director of Medical Affairs for CooperSurgical Fertility and Genomics. Prior to CooperSurgical, she was associate director-Medical Affairs for EMD Serono from 2014 to 2015. She has also served as Medical Science Liaison-Medical Affairs for Sanofi Aventis and Medical Science Liaison-Women's Health for Merck. Originally, she started her career at the Centre for Reproduction of Endangered Species at the San Diego Zoo and the Audubon Institute.